 Connection
Brian Kavanagh to CTLA-4 Antigen
This is a "connection" page, showing publications Brian Kavanagh has written about CTLA-4 Antigen.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.244 |
|
|
|
-
Robin TP, Breeze RE, Smith DE, Rusthoven CG, Lewis KD, Gonzalez R, Brill A, Saiki R, Stuhr K, Gaspar LE, Karam SD, Raben D, Kavanagh BD, Nath SK, Liu AK. Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. J Neurooncol. 2018 Oct; 140(1):55-62.
Score: 0.150
-
Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008 Aug 15; 112(4):1175-83.
Score: 0.075
-
Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|